Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, multicenter Phase I/II study to evaluate the safety and efficacy of
AT-101 in combination with topotecan in relapsed/refractory small cell lung cancer